- Home
- CLLS vs EFT Comparison
CLLS vs EFT Comparison
Compare CLLS & EFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- EFT
- Stock Information
- Founded
- CLLS 1999
- EFT 2004
- Country
- CLLS France
- EFT United States
- Employees
- CLLS N/A
- EFT N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- EFT Finance Companies
- Sector
- CLLS Health Care
- EFT Finance
- Exchange
- CLLS Nasdaq
- EFT Nasdaq
- Market Cap
- CLLS 299.0M
- EFT 306.2M
- IPO Year
- CLLS 2007
- EFT N/A
- Fundamental
- Price
- CLLS $3.22
- EFT $11.45
- Analyst Decision
- CLLS Buy
- EFT
- Analyst Count
- CLLS 1
- EFT 0
- Target Price
- CLLS $8.00
- EFT N/A
- AVG Volume (30 Days)
- CLLS 134.5K
- EFT 100.8K
- Earning Date
- CLLS 11-07-2025
- EFT 01-01-0001
- Dividend Yield
- CLLS N/A
- EFT 10.63%
- EPS Growth
- CLLS N/A
- EFT N/A
- EPS
- CLLS N/A
- EFT 1.73
- Revenue
- CLLS $63,438,000.00
- EFT N/A
- Revenue This Year
- CLLS N/A
- EFT N/A
- Revenue Next Year
- CLLS $58.00
- EFT N/A
- P/E Ratio
- CLLS N/A
- EFT $7.62
- Revenue Growth
- CLLS 223.09
- EFT N/A
- 52 Week Low
- CLLS $1.10
- EFT $11.10
- 52 Week High
- CLLS $5.48
- EFT $13.44
- Technical
- Relative Strength Index (RSI)
- CLLS 41.41
- EFT 34.83
- Support Level
- CLLS $3.12
- EFT $11.45
- Resistance Level
- CLLS $3.79
- EFT $11.58
- Average True Range (ATR)
- CLLS 0.19
- EFT 0.09
- MACD
- CLLS -0.08
- EFT 0.01
- Stochastic Oscillator
- CLLS 13.43
- EFT 29.41
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About EFT Eaton Vance Floating Rate Income Trust of Beneficial Interest
Eaton Vance Floating-rate Income Trust is a closed-end management investment company. The company's objective is to provide a high level of current income and its secondary objective is capital appreciation.